Hiroshi Ishiba

Osaka, 5450053, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan.

Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan.

Journal: World journal of gastroenterology

Published: September 11, 2025

Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S.

Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S.

Journal: Gastro hep advances

Published: January 29, 2025

Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.

Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.

Journal: Hepatology communications

Published: July 05, 2024

Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction.

Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction.

Journal: Scientific reports

Published: March 18, 2024

A case report:the progress of fascioliasis from hepatic phase to biliary phase

A case report:the progress of fascioliasis from hepatic phase to biliary phase

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: March 13, 2023

Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.

Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.

Journal: Journal of gastroenterology and hepatology

Published: December 09, 2022

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: May 01, 2021

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes.

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes.

Journal: Hepatology communications

Published: July 16, 2020

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Journal: Diagnostics (Basel, Switzerland)

Published: July 12, 2020

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.

Journal: Scientific reports

Published: May 22, 2020

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis.

Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis.

Journal: Cancers

Published: February 14, 2020

Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.

Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.

Journal: Anticancer research

Published: July 04, 2019

Showing 1-12 of 28

Last Updated: 09/26/2026